In the cutthroat pharmaceutical arena, Pfizer stands poised for a strategic pivot and a potential earnings bonanza in 2025.

British drugmaker GSK expects annual sales and profit to be towards the top of its forecast range, after second-quarter sales ...

LCNB (LCNB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Pfizer, Inc. (PFE) stock still looks cheap ahead of its upcoming Aug. 5 Q2 earnings release. Moreover, investors can make extra income by selling out-of-the-money (OTM) put options. This article ...

MSD has joined fellow big pharmas in looking to redirect cash, as the drugmaker revealed plans to save $3bn annually by the end of 2027.

Merck (MRK) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $2.28 per share a year ago. These figures are ...

Regeneron Pharmaceuticals is on the cusp of unveiling its Q2 2025 earnings this Friday, with expectations pinned at $8.53 per share and a revenue forecast of $3.30 billion. Analysts are eyeing a ...

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...

Johnson & Johnson expects full-year earnings in the range of $10.80 to $10.90 per share, with revenue in the range of $93.2 billion to $93.6 billion.

IPG has launched Agentic Systems for Commerce (ASC), to help brands manage the complex commerce ecosystem. To optimize commerce performance, ASC leverages Interpublic’s proprietary agentic system, ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Tesla expected to post double-digit declines in earnings, sales. Fed chief Powell speech in focus as central bank ...